We serve Chemical Name:2-amino-2-[3-(trifluoromethyl)phenyl]acetic acid,hydrochloride CAS:1134915-25-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![2-amino-2-[3-(trifluoromethyl)phenyl]acetic acid,hydrochloride](https://a.dearchem.com/CAS2/1134915-25-5.png)
Chemical Name:2-amino-2-[3-(trifluoromethyl)phenyl]acetic acid,hydrochloride
CAS.NO:1134915-25-5
Synonyms:2-AMINO-2-(3-(TRIFLUOROMETHYL)PHENYL)ACETIC ACID HYDROCHLORIDE;Amino[3-(trifluoromethyl)phenyl]acetic acid hydrochloride
Molecular Formula:C9H9ClF3NO2
Molecular Weight:255.62100
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:63.32000
Exact Mass:255.02700
LogP:3.29210
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-AMINO-2-(3-(TRIFLUOROMETHYL)PHENYL)ACETIC ACID HYDROCHLORIDE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Amino[3-(trifluoromethyl)phenyl]acetic acid hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-AMINO-2-(3-(TRIFLUOROMETHYL)PHENYL)ACETIC ACID HYDROCHLORIDE Use and application,Amino[3-(trifluoromethyl)phenyl]acetic acid hydrochloride technical grade,usp/ep/jp grade.
Related News: In the current trial, a total of 196 patients were randomly chosen to receive either the vaccine or a placebo. 2-amino-2-[3-(trifluoromethyl)phenyl]acetic acid,hydrochloride manufacturer Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly. 2-amino-2-[3-(trifluoromethyl)phenyl]acetic acid,hydrochloride supplier Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies. 2-amino-2-[3-(trifluoromethyl)phenyl]acetic acid,hydrochloride vendor In the current trial, a total of 196 patients were randomly chosen to receive either the vaccine or a placebo. 2-amino-2-[3-(trifluoromethyl)phenyl]acetic acid,hydrochloride factory The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses.
